Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan

Yoshimura, Akinobu; Okumura, Seiko; Sawaki, Masataka; Hattori, Masao; Ishiguro, Junko; Adachi, Yayoi; Kotani, Hirokazu; Gondo, Naomi; Kataoka, Ayumi; Iwase, Madoka; Onishi, Sachiyo; Sugino, Kayoko; Terada, Mitsuo; Horisawa, Nanae; Mori, Makiko; Takaiso, Nobue; Hyodo, Ichinosuke; Iwata, Hiroji

doi:10.1007/s12282-018-0850-z

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Riskreducing mastectomy (RRM) for hereditary breast and ovarian cancer has been covered by the NHI since April 2020 and is limited to women who have already developed breast or ovarian cancer; therefore, currently, fewer women in Japan undergo RRM and bilateral BR. 31 Types of implants covered under the NHI have been limited to Allergan products; therefore, Allergan's July 2019 recall of Biocell textured breast implants due to the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) [32][33][34][35] had a significant impact on women who had undergone implant-based reconstruction in Japan, as well as those who were undergoing the reconstruction.…”

Section: Introduction Background and Rationalementioning

confidence: 99%

Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study

et al. 2021

View full text Add to dashboard Cite

IntroductionThe aim of breast reconstruction (BR) is to improve patients’ health-related quality of life (HRQOL). Therefore, measuring patient-reported outcomes (PROs) would clarify the value and impact of BR on a patient’s life and thus would provide evidence-based information to help decision-making. The Satisfaction and Quality of Life After Immediate Breast Reconstruction study aimed to investigate satisfaction and HRQOL in Japanese patients with breast cancer who undergo immediate breast reconstruction (IBR).Methods and analysisThis ongoing prospective, observational multicentre study will assess 406 patients who had unilateral breast cancer and underwent mastectomy and IBR, and were recruited from April 2018 to July 2019. All participants were recruited from seven hospitals: Okayama University Hospital, Iwate Medical University Hospital, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Showa University Hospital, University of Tsukuba Hospital, Osaka University Hospital and Yokohama City University Medical Center. The patients will be followed up for 36 months postoperatively. The primary endpoint of this study will be the time-dependent changes in BREAST-Q satisfaction with breast subscale scores for 12 months after reconstructive surgery, which will be collected via an electronic PRO system.Ethics and disseminationThis study will be performed in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan’s Ministry of Education, Science and Technology and the Ministry of Health, Labour and Welfare, the modified Act on the Protection of Personal Information and the Declaration of Helsinki. This study protocol was approved by the institutional ethics committee at the Okayama University Graduate School of Medicine, Dentistry, on 2 February 2018 (1801-039) and all other participating sites. The findings of this trial will be submitted to an international peer-reviewed journal.Trial registration numberUMIN000032177.

show abstract

Section: Introduction Background and Rationalementioning

confidence: 99%

Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study

et al. 2021

View full text Add to dashboard Cite

show abstract

Nipple-sparing mastectomy in women at high risk of developing breast cancer

2018

View full text Add to dashboard Cite

Nipple-sparing mastectomy is a valuable addition to the options available for women at high risk of developing breast cancer. In this review, we summarize current knowledge about the high-risk genes, , and and the associated guidelines with regard to risk-reducing surgery. We consider other genetic risks and high-risk lesions. We discuss the literature on bilateral mastectomy for breast cancer risk-reduction, and the results of nipple-sparing mastectomy in particular. Finally, we report on patient satisfaction with these procedures and the impact that nipple-sparing mastectomy may have on women at high-risk of breast cancer.

show abstract

Cost–Effectiveness of BRCA1/2 Mutation Profiling to Target Olaparib Use in Patients with Metastatic Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Aim: Olaparib monotherapy improves progression-free survival in patients with metastatic breast cancer and BRCA1/2 mutations. We evaluated the cost–effectiveness of BRCA1/2 mutation profiling to target olaparib use. Methods: A Markov cohort model was generated to compare the 5-year cost–effectiveness of BRCA1/2 mutation profiling to target olaparib use. Results: The incremental cost–effectiveness ratio of BRCA1/2 mutation profiling plus olaparib monotherapy was JPY14,677,259/quality-adjusted life year (QALY) (US$131,047/QALY), compared with standard chemotherapy alone. Conclusion: BRCA1/2 mutation profiling to target olaparib use is not a cost-effective strategy for metastatic breast cancer. The strategy provides minimal incremental benefit at a high incremental cost per QALY. Hence, further cost reductions in the cost of both BRCA1/2 mutation profiling and olaparib are required.

show abstract

Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan

Abstract: Our results confirm that CRRM with reconstruction could be performed safely.

Cited by 3 publications

References 21 publications

Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study

Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study

Nipple-sparing mastectomy in women at high risk of developing breast cancer

Cost–Effectiveness of BRCA1/2 Mutation Profiling to Target Olaparib Use in Patients with Metastatic Breast Cancer

Contact Info

Product

Resources

About